Positive results from Alnylam's ALN-VSP Phase I trial for liver cancer

[News]

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has completed its Phase I study with ALN-VSP, a systemically delivered RNAi therapeutic for the treatment of advanced solid tumors with liver involvement.

More... (http://www.news-medical.net/news/20110801/Positive-results-from-Alnylams-ALN-VSP-Phase-I-trial-for-liver-cancer.aspx)

[Jackie07]

The report seems to imply it's effective for both primary liver cancer and other cancers that metastasized to the liver.